Prior work from our laboratory shows that a neuroblastoma vaccine strategy containing BET/JQ1 treated cancer cells combined with anti-CTLA4 and anti-PDL-1 checkpoint inhibitors induced robust anti-tumor immunity and cured mice with established tumors (20). Here, CTLA4 is linked to neuroblastoma.